Bristol Myers Squibb (BMS) acquired Karuna Therapeutics, the developer of KarXT, in a deal worth US $14.0 billion in equity value that completed ​ earlier this year. The deal has paid off as Karuna’s lead asset was approved ​ last week by the US FDA.

PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in adults. With this approval, the company is entitled to receive two separate payments totalling $29m from Royalty Pharma and Karuna Therapeutics,

After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has borne fruit with the approval of a promising new drug. | Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has borne fruit with the approval of a promising new schizophrenia drug.

No new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric disorder.

The FDA has approved the first treatment for schizophrenia that targets cholinergic receptors rather than dopamine receptors.

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite potential risks. Read more on BMY here.

Cobenfy was approved to reduce the psychotic symptoms associated with schizophrenia. It is a new type of medicine that works by stimulating a pair of muscarinic receptors in the brain, that, in turn, control the release of a brain chemical called acetylcholine.

Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The medication introduces a new approach by targeting M1 and M4 receptors without blocking D2 receptors.

The US Food and Drug Administration has approved Cobenfy, also known as KarXT, a new schizophrenia treatment. The drug was developed by Karuna Therapeutics, which was bought by Bristol Myers Squibb (BMS) last year for $14 billion.

The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating schizophrenia. The fixed dose combination of xanomeline-trospium is the first to act via a novel mechanism for the serious psychiatric disorder in over 50 years,

On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of drugs for schizophrenia in more than 30 years.